Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Buy” from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STROGet Free Report) have been given an average rating of “Buy” by the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $12.50.

STRO has been the topic of a number of recent research reports. Piper Sandler restated an “overweight” rating and issued a $11.00 price objective (down previously from $12.00) on shares of Sutro Biopharma in a report on Wednesday, April 3rd. Bank of America began coverage on shares of Sutro Biopharma in a report on Wednesday, May 8th. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a report on Tuesday, May 14th. JMP Securities restated a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a research report on Wednesday, April 3rd. Finally, Truist Financial lowered their price objective on shares of Sutro Biopharma from $25.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd.

View Our Latest Stock Report on STRO

Sutro Biopharma Price Performance

STRO opened at $3.99 on Thursday. Sutro Biopharma has a one year low of $2.01 and a one year high of $6.13. The firm has a market capitalization of $326.34 million, a P/E ratio of -2.12 and a beta of 1.24. The company has a fifty day moving average price of $4.23 and a 200-day moving average price of $4.12.

Sutro Biopharma (NASDAQ:STROGet Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.03). The business had revenue of $13.01 million during the quarter, compared to the consensus estimate of $11.57 million. Sutro Biopharma had a negative return on equity of 94.18% and a negative net margin of 74.61%. On average, analysts expect that Sutro Biopharma will post -3.19 earnings per share for the current year.

Institutional Investors Weigh In On Sutro Biopharma

Several large investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. grew its position in Sutro Biopharma by 1,275.7% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,105,132 shares of the company’s stock worth $10,775,000 after purchasing an additional 2,879,412 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Sutro Biopharma by 18.2% during the third quarter. Acadian Asset Management LLC now owns 773,867 shares of the company’s stock valued at $2,684,000 after purchasing an additional 119,399 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in Sutro Biopharma by 42.5% during the fourth quarter. Vontobel Holding Ltd. now owns 641,684 shares of the company’s stock valued at $2,753,000 after purchasing an additional 191,345 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in Sutro Biopharma by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 35,856 shares of the company’s stock valued at $154,000 after purchasing an additional 9,092 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Sutro Biopharma by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 40,779 shares of the company’s stock valued at $175,000 after purchasing an additional 8,314 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

(Get Free Report

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Read More

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.